Alpha 2 -adrenergic agonists given intrathecally result in antinociception and intracerebroventricularly (ICV) in sedation. To examine whether different alpha 2 -adrenergic receptor subtypes differentially mediate antinociception and sedation, we measured the relative potency of three alpha 2 -adrenergic agonists, dexmedetomidine (DMET), clonidine (CLON) and UK-14.304 (UK), after spinal and ICV administration. Each agonist was given either alone or in the presence of systemically administered yohimbine, which acts as a competitive alpha 2 -antagonist in unanaesthetized rats. Intrathecal delivery of the agonists alone resulted in a dose-dependent antinociceptive effect (ED 50 (nmol): DMET:1.2, UK:1.7, CLON:5.6) with little sedative effect at the lower doses. Yohimbine pretreatment resulted in a rightward shift of the dose-response curves (DMET9CLON9UK). ICV alpha 2 -adrenergic agonists produced a dose-dependerit sedation (ED 50 (nmol): DMET:10.5; UK:28.7; CLON:126), with little antinociceptive action. Again, yohimbine pretreatment produced a right shift of the ICV sedation dose-response curves (UK9DMET9 CLON). Thus, we conclude that the spinal analgesic effects of DMET, CLON and UK appear to be mediated by two sites. After ICV delivery, DMET, CLON and UK appear to act at a common supra-spinal site to produce sedation and this site resembles that acted upon by UK in the spinal cord. (Br.
Alpha 2 -adrenergic agonists given intrathecally result in antinociception and intracerebroventricularly (ICV) in sedation. To examine whether different alpha 2 -adrenergic receptor subtypes differentially mediate antinociception and sedation, we measured the relative potency of three alpha 2 -adrenergic agonists, dexmedetomidine (DMET), clonidine (CLON) and UK-14.304 (UK), after spinal and ICV administration. Each agonist was given either alone or in the presence of systemically administered yohimbine, which acts as a competitive alpha 2 -antagonist in unanaesthetized rats. Intrathecal delivery of the agonists alone resulted in a dose-dependent antinociceptive effect (ED 50 (nmol): DMET:1.2, UK:1.7, CLON:5.6) with little sedative effect at the lower doses. Yohimbine pretreatment resulted in a rightward shift of the dose-response curves (DMET9CLON9UK). ICV alpha 2 -adrenergic agonists produced a dose-dependerit sedation (ED 50 (nmol): DMET:10.5; UK:28.7; CLON:126), with little antinociceptive action. Again, yohimbine pretreatment produced a right shift of the ICV sedation dose-response curves (UK9DMET9 CLON). Thus, we conclude that the spinal analgesic effects of DMET, CLON and UK appear to be mediated by two sites. After ICV delivery, DMET, CLON and UK appear to act at a common supra-spinal site to produce sedation and this site resembles that acted upon by UK in the spinal cord. (Br. J. Anaesth. 1998; 81: 208-215) Keywords : receptors, adrenergic; sympathetic nervous system, clonidine; anaesthesia, depth; analgesic techniques, subarachnoid; rat Alpha 2 -adrenoceptor agonists produce powerful dose-dependent analgesia in animals 1 2 and in humans 3 4 when delivered into the intrathecal space. This analgesia is believed to result from an agonist interaction with presynaptic alpha 2 -adrenergic receptors located on small primary afferents, which decreases the release of transmitter. [5] [6] [7] [8] In addition these agonists are thought to interact with postsynaptic alpha 2 -adrenergic receptors on projection neurons, hyperpolarizing the cell by increasing potassium conductance through Gi coupled K ; channels. 9 In addition to their subarachnoid analgesic activity, alpha 2 -agonists produce dose-dependent sedation and EEG synchronization at supraspinal sites. The mechanism for the sedative response is believed to be similar to the analgesic action and is mediated through postsynaptic alpha 2 -adrenoreceprors and inhibitory G proteins. [10] [11] [12] Microinjection studies have pointed to several brainstem sites, including the locus coeruleus, 11 which may subserve these effects. After spinal delivery, sedation is occasionally observed and is considered to reflect supra-spinal redistribution of the spinally delivered agent. 13 Over the past years, it has been become apparent that there are several subclasses of the alpha 2 -adrenergic receptor. At least three different subtypes: 2A, 2B and 2C have been described based on pharmacological properties. Cloning studies in rat and human tissue confirmed that several distinct subtypes exist. [14] [15] [16] [17] [18] [19] In recent studies, we have found that alpha 2 -adrenergic agonists exert their antinociceptive action at two sites, each having different yohimbine sensitivities. 20 Interestingly, at high spinal doses, one class of agonists appears to be associated with sedation while the other is not. 20 This suggests the possibility that supra-spinal sedation may be mediated by distinct alpha 2 -adrenergic receptor subtypes. To determine if the different effects are mediated by sites with different affinity for this antagonist, we examined the effects of three spinal and intracerebroventricular (ICV) administered alpha 2 -adrenergic agonists alone and in the presence of systemically delivered yohimbine. The efficacy of a competitive antagonist, yohimbine, is proportional to its potency for the alpha 2 -adrenoreceptor site. Thus differences in the antagonist's efficacy in reversing equieffective doses for analgesia or sedation of the alpha 2 -adrenoreceptor agonists (clonidine, dexmedetomidine or UK 14.304) would suggest different receptor subtypes are involved in each response. In addition by using prazosin, a competitive antagonist, which predominantly inhibits alpha 1 -adrenoceptor mediated effects, the observed antinociceptive or sedative activity could be localized to the alpha 2 -receptor. Alternately, a similar dose-response shift for analgesia and sedation for the three agonists in the presence of yohimbine would provide pharmacological evidence that the stimulation of a similar alpha 2 -adrenergic receptor subtype results in both, analgesia and sedation. The rationale for the use of the dose-ratio analysis has been more extensively reviewed elsewhere.
Materials and methods
Animal surgery and testing procedures were approved by the institutional animal care committee of the University of California, San Diego. All procedures were performed according to these guidelines. Rats (male Sprague-Dawley, Harlan Industries, Indianapolis, IN, USA; 300-350 g) were implanted with intrathecal catheters and thereafter kept in separate cages on a 12-h light-dark cycle and given water and food ad libitum. Each rat was implanted as described below with an intrathecal catheter or an ICV cannula, or both. Animals were randomly assigned to treatment groups. The animals were anaesthetized and killed after the experiment was completed.
ANIMAL PREPARATION
For the spinal delivery of study drugs animals were prepared with intrathecal (i.t.) catheters in a modified version of techniques described previously. 23 Only animals with normal motor function after i.t. placement were used in the following experiments. ICV cannula insertion was performed using a modified version of the technique of Moron, Stevens and Yaksh. 24 Briefly, before surgery animals were anaesthetized with halothane (2-3% in 50% oxygen/air), breathing spontaneously via mask ventilation. For ICV cannulation a cranial burr hole (0.5 mm lateral to the sagittal suture and 0.5 mm caudal to the coronal suture, adjacent to the bregma) was made. The ICV cannula (23-gauge stainless steel: 15 mm in length) was lowered 3 mm beyond the dura into the left lateral ventricle. The cannula was fixed with cranioplastic cement to three stainless steel bone screws. After all surgical procedures, a recovery period of five days was allowed before starting the injection series.
ICV/IT INJECTION
Drugs were administered by a microinjection syringe attached to the indwelling catheters via a length of calibrated PE-90 tubing. For the i.t. studies, drugs were injected in a volume of 10 l followed by 10 l normal saline to flush the catheter. For ICV injections, the drug was delivered in a volume of 10 l followed by 2 l of saline to flush the cannula. TEST 
MEASURES
For each drug, the following test measures were obtained before drug delivery and at 5, 10, 15, 20, 30 min after drug delivery.
Antinociception
The threshold for thermal stimuli was assessed by an observer blinded to the drug injected either ICV or i.t. using a technique previously described. 25 Each animal was placed in a Plexiglas cage (9 22 25 cm) on top of a glass plate with a surface temperature maintained at 30ЊC by a feedback-controlled heater fan. The animal was left on this surface for at least 15 min before any stimulation to allow for proper adaptation. The thermal stimulus was manoeuvred under the glass to focus the projection bulb on the plantar surface of the paw. Initiation of the current to the halogen bulb started a timer. Bulb current was automatically terminated when paw elevation was sensed by photo diodes or when an interval of 20 s (cut-off time) had passed. Aiming of the focused stimulus was reliably accomplished by a mirror attached to the stimulus which permitted visualization of the undersurface of the paw. Light beam intensity was monitored by a measurement of bulb current and the stimulus intensity was calibrated daily by assessing the temperature change after 10 s sensed by an underglass thermocouple (T1/2:0.2 s). The intensity of the light was adjusted and maintained at baseline latencies of 10.2 s (0.6 SEM). Withdrawal latency to the nearest 0.1 sec were measured for both paws. The first measurement was made on both hind paws, the response latencies averaged and counted as baseline score (time 0). Tests were then made at 5, 10,15, 20, 30 min after drug delivery.
Sedation
To score the behavioural changes before and during treatment of the animal, a sedation index was used. The index consisted of five behavioural parameters which have been shown to be blocked by opioids in a dose-dependent manner. 25 These measured responses included: pinna reflex, cornea reflex (both evoked by light touch of the surface of pinna or cornea with a small piece of PE-10 tubing), evoked movement (startle reflex evoked by tapping on the cage wall), signs of spontaneous movement (for example, grooming, chewing, ambulating) and assessment of the righting reflex. Each parameter was scored as follows: 0:normal (brisk pinna/cornea reflex response or startle reflex; spontaneous movement within 30 s of the assessed time-point; righting reflex was performed immediately after turning the animal on its back); 1:attenuated (touch with tubing for pinna or cornea reflex or knocking on cage wall does result in a slow reflex behaviour and has to be repeated, touch or knocking has to be repeated at least twice) or 2:completely absent (no reflex was shown after touching cornea three times or pinna both sides, no startle behaviour was displayed after knocking against cage wall three times and no spontaneous movement or righting reflex was observed for 9than 1 min). To permit a quantitative assessment, the supra-spinal side-effects index was used which consisted of summing the individual scores for the five measurements at each time point, permitting a total score of 10 (5 2 Typically, rats were randomized for three sets of experiments.
(1) Agonist dose-response curves were obtained for i.t. and ICV drug administration. Dose-response curves served to define the near maximal dose for each drug for each route of administration. Each animal was used in 3-5 single experiments, animals were randomized to receive CLON, DMET or UK. Time-course curves were used to establish the time of peak agonist action for subsequent antagonistagonist interaction studies.
(2) Antagonist dose-response studies were carried out in which a near maximally effective dose of agonist was delivered i.v. or ICV alone, or after the injection of yohimbine (0.
91 i.p.; 10 min before agonist injection). To establish the time course of the maximal effect of the antagonist, a fixed dose of agonist was administered i.t. and a maximal dose of antagonist was injected at different time intervals. The measurements indicated that a maximum degree of antagonism was observed, reliably within 10-15 min after injection of antagonist for all three agonists (data not shown).
(3) Agonist dose-response curves were carried out alone or in the presence of a fixed dose of yohimbine (1 mg kg 91 i.p.) given 10 min before administering the agonist.
Dose ratios then were calculated, being defined as the ratio of the ED 50 of the analgesic or sedative response with the antagonist divided by the ED 50 of the agonist without the antagonist. 3 g)) (fig. 2 ). An increase in the sedation index after i.t. administration was observed only in the DMET group (table 1) . In control animals, vehicle administration did not produce a significant effect on analgesic or sedative variable (see below).
The administration of a competitive antagonist, yohimbine (1 mg kg 91 i.p.) resulted in a rightward shift of the antinociceptive effect of DMET (dose ratio:8.3), CLON (dose ratio:4.2) and UK (dose ratio:2.1) ( fig. 2 and table 1 fig. 4 ). Prazosin reduced the sedation index for DMET ( fig. 6 ).
Discussion
Alpha 2 -adrenergic agonists produce sedation and antinociception at supra-spinal and spinal sites and these effects are reversed in a dose-dependent fashion by yohimbine. Previous studies have raised the possibility of different yohimbine-sensitive alpha 2 -adrenergic receptors. 20 We sought to investigate further this interaction by systematically examining the pharmacology of three alpha 2 -agonists in the presence of yohimbine. The purpose of our study was to compare: (a) the efficacy after i.t. and ICV delivery of several agonists in producing antinociception and sedation, respectively, and (b) to assess the ability of systemic yohimbine to reverse the i.t. (antinociception) and ICV (sedation) effects of these agonists. The efficacy of the competitive antagonist, yohimbine, is proportional to its affinity for the alpha 2 -adrenergic receptor. 21 22 27 Thus differences in the magnitude of the dose-response shift for either the analgesic or sedative response of the three agonists in the presence of a fixed dose of the competitive antagonist, for example, yohimbine, would suggest differences of the involved alpha 2 -adrenergic receptor sites for analgesia or sedation. Alternately, if the magnitudes of the rightward shift observed for a given i.t. or ICV agonist in producing antinociception or sedation are similar, this should provide information about the similarity of the involved alpha 2 -adrenergic receptor sites. Dissimilar shifts would suggest an interaction with brain sites and spinal sites for which yohimbine has a distinct affinity. I.T. ALPHA 2 -ADRENERGIC RECEPTORS I.t. administration of each of the three agonists resulted in dose-dependent analgesia, a finding which confirms other investigations. 20 28 29 Their relative efficacies in eliciting analgesia is similar to that described by others. 29 30 After i.t. administration, CLON and UK produced only a modest sedation score, even at the highest doses. Dexmedetomidine, however, produced dose-dependent sedation after i.t. administration. The appearance of sedation after spinal DMET is likely to be because of the greater supra-spinal redistribution secondary to the higher lipid solubility of DMET in comparison with CLON (octanol: buffer partition coefficient of 2.8 for DMET vs 0.8 for CLON). 31 32 Pretreatment with yohimbine produced a rightward shift in the analgesia dose-response curve of i.t. administered alpha 2 -agonists. The ordering of the rightward shift of DMET and CLON is comparable to the ratio found by Eisenach and colleagues. 31 The greater shift of DMET in the presence of the competitive antagonist raises several possible explanations. In binding studies, 33 the competitive antagonist yohimbine was used to reveal several populations of alpha-adrenergic receptors with differing agonist affinities. The most simplistic interpretation is that the prominent dose-response shift of DMET supports a high affinity of DMET for a yohimbinesensitive subtype which mediates analgesia. Based on binding data reported by Uhlen and Wikberg 34 the predominant alpha 2 -subtype in the rat spinal cord is the alpha 2 A-adrenoceptor. This is in agreement with binding studies of alpha 2 -adrenoceptors in the human spinal cord. 35 However, there is also well established evidence for the existence of additional subtypes (alpha 2D -adrenoceptors) in the rat. 35 Thus, while the concept of spinal non-A sites may be controversial, the functional and pharmacological, differences provide support that DMET is acting at different sites within the spinal cord. Importantly, spinal UK produced only modest sedation, though this difference may be attributable to kinetics of redistribution.
ICV ALPHA 2 -ADRENERGIC RECEPTORS ICV administration of alpha 2 -agonists produce a sedative response. 11 12 36 The mechanisms of this effect are not clear, but might be correlated with an inhibition of activity in the locus coeruleus of the brain stem.
11 Analgesia after ICV injection of alpha 2 -adrenergic agents has also been reported. 37 38 The quantitative magnitude of the antagonist action, as defined by the respective dose ratios, revealed no significant differences across the three agonists. This observation suggests that the supra-spinal sedative responses were mediated through an alpha 2 -adrenergic receptor for which yohimbine has approximately equal affinity-that is, these compounds act through a common alpha 2 -adrenergic receptor.
After ICV injection, DMET and CLON and, to a modest degree, UK produced an increase in the thermal response latency. The analgesic action of UK was shown to be less potent than its sedative action. 37 The analgesic action of alpha 2 -adrenergic agonists after supra-spinal administration could be caused by systemic redistribution and subsequent spinal action. 13 However, we note that the antinociceptive effects of spinal DMET were extremely sensitive to i.p. yohimbine. Thus the degree of the rightward shift in the ED 50 for antinociception after i.t. delivery of DMET was approximately 8 vs 2, after ICV injection of DMET, respectively. In contrast, the similarity of the ratios for the sedative and the analgesic effects of ICV DMET argue that both effects are mediated through the same alpha 2 -adrenergic receptor. In this regard, it is not clear whether the increase in hind paw withdrawal latency is a specific mechanism or is secondary to sedation. This alternative would explain tne similarity in the ICV dose ratios for sedation and antinociception.
Prazosin, an alpha 1 -antagonist with some alpha 2non-A -antagonist effects increased the sedative response of CLON and UK after i.t. delivery (statistically significantly), supporting the speculation that inactivation of the sedative response mediated by an alpha 2 -adrenoreceptor is reversed through stimulation of alpha 1 -adrenoceptors. In conclusion, the present observations raise the possibility that the three alpha 2 -adrenergic agonists may exert their sedative effects at a supra-spinal site for which yohimbine has a common affinity. In contrast, in the spinal cord, these three agents appear to act upon at least two sites, as defined by the differential potency of yohimbine in reversing agonist effect. These studies thus join a body of pharmacological data which suggests that there may be two spinal sites which can induce analgesia and a single supra-spinal site that results in sedation. Given the similarity of the site in brain and spinal cord as defined by the apparent potency of yohimbine, one of the spinal sites is similar to that site in brain which yields sedation. Further developments in this area may well provide a tool for which a selective analgesia may be induced by an alpha 2 -adrenergic interaction without sedation.
